Evkeeza Market Report 2026: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

The growth in the historic period can be attributed to limited effectiveness of traditional statins, historical burden of familial hypercholesterolemia, early biologic lipid therapies, unmet needs in hofh patients, specialist driven treatment adoption.

The growth in the forecast period can be attributed to increasing genetic screening for lipid disorders, rising adoption of biologics, expanding reimbursement for rare diseases, advancements in lipid metabolism research, growing specialty cardiology centers. Major trends in the forecast period include expansion of monoclonal antibody therapies, rising focus on rare lipid disorders, growth in precision lipid lowering treatments, increasing use of targeted angptl3 inhibitors, improved outcomes in severe hypercholesterolemia.

The rising prevalence of genetic disorders is expected to drive the growth of the evkeeza market in the coming years. Genetic disorders are conditions caused by abnormalities in an individual’s DNA, which may result from mutations in one or more genes or alterations in the structure or number of chromosomes. The increase in genetic disorders is driven by improved diagnostic technologies and environmental factors that contribute to the occurrence of genetic conditions. Evkeeza is used to treat homozygous familial hypercholesterolemia (HoFH), a genetic disorder, by inhibiting ANGPTL3 to lower LDL cholesterol levels in affected patients. For example, in June 2024, the American Society of Hematology, a US-based non-profit organization, projected that by 2050, the global population of individuals with sickle cell disease (SCD) will increase by approximately 30%. Therefore, the rising prevalence of genetic disorders is fueling the growth of the evkeeza market.

The growing number of drug approvals is also expected to drive the expansion of the evkeeza market in the coming years. Drug approvals are formal processes through which regulatory authorities evaluate and authorize pharmaceutical drugs for public use. The rise in approvals is largely driven by advancements in biotechnology, which accelerate drug discovery, and supportive regulatory frameworks such as accelerated approval programs that streamline access for high-need medications. Drug approvals support Evkeeza growth by expanding its availability for treating HoFH, improving patient access, and leveraging incentives such as orphan drug exclusivity. For example, in February 2024, the Personalized Medicine Coalition, a US-based non-profit organization, reported that in 2023, the FDA approved 16 new personalized treatments for rare disease patients, a significant increase from six approvals in 2022. Therefore, the increasing number of drug approvals is driving growth in the evkeeza market.

A key trend in the evkeeza market is obtaining regulatory approvals to expand access and strengthen its position in treating patients with HoFH. Regulatory approvals involve formal authorization by government or regulatory agencies to market and use a drug, medical device, or treatment in the public domain. For instance, in March 2023, Regeneron Pharmaceuticals Inc., a US-based biotechnology company, received FDA approval for Evkeeza (evinacumab-dgnb) for children aged 5 to 11 years with HoFH, a rare genetic disorder causing extremely high LDL cholesterol levels. This marked the first approval of an ANGPTL3 inhibitor for this age group, providing a treatment option for approximately 1,300 affected children in the U.S. Clinical trials demonstrated that children treated with Evkeeza alongside other lipid-lowering therapies experienced an average 48% reduction in LDL-C levels after 24 weeks.

Major companies operating in the evkeeza market are Regeneron Pharmaceuticals Inc.

North America was the largest region in the evkeeza market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the evkeeza market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the evkeeza market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

Tariffs have impacted the evkeeza market by increasing costs associated with monoclonal antibody production, bioprocessing equipment, and temperature controlled logistics. These effects are most evident in hospital infusion and specialty pharmacy segments, particularly in regions dependent on imported biologics such as asia pacific and parts of europe. Higher tariffs can influence therapy affordability and delay patient access in cost sensitive healthcare systems. At the same time, tariffs are encouraging localized biologics manufacturing, regional supply chain development, and long term investment in domestic pharmaceutical capabilities.

The evkeeza market research report is one of a series of new reports that provides evkeeza market statistics, including evkeeza industry global market size, regional shares, competitors with a evkeeza market share, detailed evkeeza market segments, market trends and opportunities, and any further data you may need to thrive in the evkeeza industry. This evkeeza market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Evkeeza (evinacumab) is a monoclonal antibody used to treat homozygous familial hypercholesterolemia (HoFH), a rare genetic disorder characterized by high cholesterol levels. It functions by inhibiting angiopoietin-like 3 (ANGPTL3), helping to reduce LDL cholesterol and other lipid levels in affected patients.

The main types of indications for evkeeza are primary hypercholesterolemia and homozygous familial hypercholesterolemia. Primary hypercholesterolemia refers to elevated blood cholesterol levels caused by genetic or hereditary factors rather than secondary causes such as lifestyle or other medical conditions. It can be administered via intravenous (IV) infusion, self-administered subcutaneous (SC) injections, hospital infusion centers, and ambulatory care settings, and is distributed through hospital pharmacies, specialty pharmacies, and online pharmacies.

The evkeeza market consists of sales of products including Repatha (evolocumab), Praluent (alirocumab), and Lomitapide. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.